[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,961
Citations 0
Editor's Note
February 2015

Confronting Bias

JAMA Intern Med. 2015;175(2):307. doi:10.1001/jamainternmed.2014.6933

For more than 20 years, steady progress has been made along the road to clinical trial transparency. What started with steps taken by medical journals, including disclosure of trial funding, disclosure of authors’ conflicts of interest, publication of trial protocols, and statements of authors’ contributions, has been strengthened by recent advances to require publicly accessible clinical trial registration and results reporting. Encouragingly, progress continues to be made, as there is now considerable momentum toward clinical trial data sharing. Each of these steps was taken with the intention to reduce the potential for bias in the peer-reviewed literature, mitigating problems such as selective publication and selective outcome reporting or guest authorship and ghostwriting and ensuring that research findings are fully disseminated, fairly and objectively, in a way that allows an informed assessment of the evidence.